Rani Therapeutics Confirms Nasdaq Listing for Class A Common Stock

Ticker: RANI · Form: 8-K · Filed: Feb 5, 2024 · CIK: 1856725

Rani Therapeutics Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyRani Therapeutics Holdings, Inc. (RANI)
Form Type8-K
Filed DateFeb 5, 2024
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, stock-listing

TL;DR

**RANI's Class A common stock remains listed on Nasdaq, business as usual.**

AI Summary

Rani Therapeutics Holdings, Inc. filed an 8-K on February 5, 2024, to disclose that its Class A common stock, with a par value of $0.0001 per share, is registered on The Nasdaq Stock Market LLC under the trading symbol RANI. This filing, under Items 7.01 (Regulation FD Disclosure) and 8.01 (Other Events), primarily serves to update its public record regarding its listed securities. For investors, this simply confirms the continued listing of RANI stock on Nasdaq, which is important for liquidity and market access.

Why It Matters

This filing confirms Rani Therapeutics' continued listing on The Nasdaq Stock Market LLC, which is crucial for the stock's liquidity and accessibility to investors.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure confirming existing information and does not introduce new risks or significant changes.

Analyst Insight

This filing is a routine administrative update. Smart investors should note the confirmation of RANI's Nasdaq listing but understand that this 8-K does not contain new material information that would typically drive investment decisions.

Key Numbers

  • $0.0001 — Par Value per Share (This is the nominal value assigned to each share of Class A common stock.)

Key Players & Entities

  • Rani Therapeutics Holdings, Inc. (company) — the registrant filing the 8-K
  • The Nasdaq Stock Market LLC (company) — the exchange where RANI's stock is registered
  • $0.0001 (dollar_amount) — par value per share of Class A common stock
  • RANI (company) — trading symbol for Class A common stock
  • February 05, 2024 (date) — date of earliest event reported

FAQ

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant as specified in its charter is Rani Therapeutics Holdings, Inc.

On which stock exchange is Rani Therapeutics Holdings, Inc.'s Class A common stock registered?

Rani Therapeutics Holdings, Inc.'s Class A common stock, with a par value of $0.0001 per share, is registered on The Nasdaq Stock Market LLC.

What is the trading symbol for Rani Therapeutics Holdings, Inc.'s Class A common stock?

The trading symbol for Rani Therapeutics Holdings, Inc.'s Class A common stock is RANI.

What was the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was February 05, 2024.

What is the business address and phone number of Rani Therapeutics Holdings, Inc.?

The business address is 2051 Ringwood Avenue, San Jose, California, 95131, and the business phone number is (408) 457-3700.

Filing Stats: 1,091 words · 4 min read · ~4 pages · Grade level 11 · Accepted 2024-02-05 08:10:21

Key Financial Figures

  • $0.0001 — tered Class A common stock, par value $0.0001 per share RANI The Nasdaq Stock Mar

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 5, 2024, Rani Therapeutics Holdings, Inc. (the "Company" or "Rani") issued a press release to announce topline results from the RT-111 Phase 1 clinical trial. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company is also furnishing a copy of a presentation (the "Presentation") that the Company intends to use, in whole or in part, during discussions with external parties. A copy of the Presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. All of the information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On February 5, 2024, Rani announced topline results from the RT-111 Phase 1 clinical trial. Study Design A single-center, open-label Phase 1 study of RT-111, a RaniPill capsule containing ustekinumab biosimilar, was conducted in Australia. The study evaluated the safety and tolerability of a single administration of RT-111 in healthy adult volunteers. Of the 55 participants, 20 orally ingested RT-111 containing a single 0.5mg dose of ustekinumab biosimilar and 20 orally ingested RT-111 containing a single 0.75mg dose of ustekinumab biosimilar, while a control group of 15 participants received a single 0.5mg subcutaneous (SC) injection of STELARA (ustekinumab), a commercial formulation of ustekinumab. Participants were fasted overnight prior to dose administration. Blood samples were collected at various time points over 60 days and analyzed for ustekinumab concentrations. Blood samples were analyzed for anti-drug antibodies at three timepoints. Topline Results Safety and Tolerability RT-111 was generally well tolerated, with no serious adverse events (SAEs) noted during the study o None of the participants withdrew from the study due to any adverse event o Two subjects in the 0.5mg RT-111 group and one subject in the 0.5mg SC STELARA group had mild, transient adverse events which resolved without any intervention There was no meaningful difference in incidence of anti-drug antibodies via the RaniPill route of delivery compared to STELARA SC injection Stelara SC 0.50 mg N=15 RT-111 0.50 mg N=20 RT-111 0.75 mg N=20 Drug Signal Detected N=15 N=19 N=16 Number of ADA Positive Cases Total ADA Positive* N 4 2 6 % 27% 11% 38% * ADA positive post dosing, increase in titer compared to pre-dose level No participants reported difficulty swallowing the capsule and capsule remnants passed from all participants without sequelae Pharmacokinetics Oral RT-111 delivered 0.5mg and 0.75mg of uste

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release of Rani Therapeutics Holdings, Inc. dated February 5, 2024 99.2 Presentation dated February 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Rani Therapeutics Holdings, Inc. Date: February 5, 2024 By: /s/ Svai Sanford Svai Sanford Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.